Dose Escalation Methods in Phase I Cancer Clinical Trials
Christophe Le Tourneau(Institut Curie), Lillian L. Siu(University Health Network)
Cited by 856
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Toward understanding and exploiting tumor heterogeneity
|Nature Medicine|2015|770
Small molecules, big impact: 20 years of targeted therapy in oncology
|The Lancet|2020|606
Preliminary Results of a Randomized Study on Therapeutic Gain by Concurrent Chemotherapy for Regionally-Advanced Nasopharyngeal Carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group
|Journal of Clinical Oncology|2005|448
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
|New England Journal of Medicine|2025|277